Cystic Fibrosis Industry Growth & Market Trends Analysis to 2019

1
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 CFTR Modulators Initiate Drive
towards Personalized Treatment and Market
GrowthbyGBI Research

• Explore all reports for  Respiratory
  Therapeutics market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/respiratory-ther
  apeutics .

2
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• Research Report, a leading business intelligence
  provider, has released its latest research report
  Cystic Fibrosis Therapeutics in Major Developed
  Markets to 2019 CFTR Modulators Initiate Drive
  towards Personalized Treatment and Market
  Growth. The value of the Cystic Fibrosis (CF)
  market is expected to increase significantly in
  value over the forecast period across the leading
  eight developed nations, from 695.6 million in
  2012 to almost 4.5 billion in 2019. This equates
  to a Compound Annual Growth Rate (CAGR) of 30.4.
  Novel treatments with disease-modifying
  mechanisms of action are the primary factor
  driving the growth of the value of the market.
  The positive impact of new market entrants will
  offset the effects of key patent losses during
  the forecast period.
• Cystic Fibrosis Transmembrane conductance
  Regulators (CFTR) modulators are the first type
  of CF therapy to treat the root cause of the
  disease rather than the symptoms, and as a
  result, they offer patients improved relief and
  quality of life. Kalydeco (ivacaftor), which has
  been marketed since 2012, was the first CFTR
  modulator to reach the market, and despite only
  treating a small proportion of the CF population,
  it had a large impact on the value of the market.
  This effect will be repeated on a larger scale
  when lumacaftor and Ataluren (PTC124) enter the
  market, as these treatments can be used for a
  much larger proportion of the CF population.
  Vertex Pharmaceuticals Inc. are the developers of
  Kalydeco, lumacaftor and other early phase CFTR
  modulators, and are therefore expected to play a
  key role in the development of the future CF
  market.
• Inquire for Discount _at_ http//www.rnrmarketresearc
  h.com/contacts/discount?rname148418 .

3
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• The pricing of CFTR modulators will be premium
  due to the clinical benefits and
  disease-modifying effects that they represent.
  Symptomatic therapies will be used in conjunction
  with CFTR modulators, and will still be a
  necessary part of the CF treatment plan. The
  antibiotics segment in particular is expected to
  become overcrowded and competitive over the
  forecast period, due to cheap, generic tobramycin
  products and novel market entrants competing for
  market share.
• Scope
• The report assesses the current CF market, and
  predicts market trends to 2019, analyzing key
  drivers and barriers. The areas covered include -
• A disease introduction, which defines the
  disease, including symptoms, diagnosis and
  treatment.
• An analysis of the CF marketed landscape,
  including a comparison of the efficacy and safety
  of the most prominent brands, as well as the
  unmet needs of CF treatment.
• A detailed analysis of the CF pipeline,
  detailing, among other parameters, drug
  distribution by phase, molecule type and
  mechanism of action. The CF clinical trial
  landscape is then analyzed, with a particular
  emphasis on failure rates across different trial
  phases as well as the trends in clinical trial
  size and duration. This section also includes
  profiles and single product forecasts for the
  most promising pipeline drugs.
• Complete Report Available _at_
• http//www.rnrmarketresearch.com/cystic-fibrosis-t
  herapeutics-in-major-developed-markets-to-2019-cft
  r-modulators-initiate-drive-towards-personalized-t
  reatment-and-market-growth-market-report.html .

4
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• An epidemiological forecast of the major CF
  markets. The projected values include total and
  treated populations.
• An in-depth forecasting model for the CF market,
  which considers the current marketed therapies,
  in addition to the potential entry of new
  products into the market. The model consists of a
  projected outcome, with high and low variance
  results, depending on the potential performance
  of pipeline therapies.
• Analysis of strategic consolidations within the
  CF indication, including co-development and
  licensing agreements.
• An overview of the drivers and barriers for the
  CF market is also included.
• Reasons to buy
• The report enables clients to develop a strong
  understanding of CF as a disease and a market.
  The current therapeutic needs and future market
  trends contained in this report will highlight
  market opportunities and the scope of competition
  between CF therapeutics. Primarily, the report
  will allow clients to -
• Buy a copy of report _at_
• http//www.rnrmarketresearch.com/contacts/purchase
  ?rname148418 .

5
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• Understand the CF pipeline and the clinical needs
  it is addressing. In particular, the importance
  and benefits of CFTR modulators are highlighted
  and compared with symptomatic treatments.
• Develop their knowledge of key products that may
  enter the market before 2019. Detailed profiles
  of these products are provided, with a focus on
  their clinical trial performance, as well as how
  they can be incorporated into the CF treatment
  plan and what competition they face.
• Assess the risk associated with CF clinical
  trials compared with both industry and therapy
  area averages. In addition, in order to
  understand the trends in both trial size and
  duration according to mechanism of action or
  molecule type.
• Identify patterns of growth in the CF market over
  the forecast period and understand the underlying
  causes, as well as observing the contributions
  made by each major market to this growth.
• Request Sample copy of this report _at_
• http//www.rnrmarketresearch.com/contacts/request-
  sample?rname148418 .

6
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.